Inadequate statistical power of published comparative cohort studies on ventilator-associated pneumonia to detect mortality differences

Clinical Infectious Diseases

Volumn 50, Issue 4, 2010, Pages 468-472

  Falagas, Matthew E ^a,b,e   Kouranos, Vasilios D ^a   Michalopoulos, Argyris ^a,c   Rodopoulou, Sophia P ^a,d   Athanasoulia, Anastasia P ^a   Karageorgopoulos, Drosos E ^a  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b Department of Medicine ^*  (Greece)

^c HENRY DUNANT HOSPITAL   (Greece)

^d NATIONAL TECHNICAL UNIVERSITY OF ATHENS   (Greece)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; HUMAN; MORTALITY; PRIORITY JOURNAL; PUBLICATION; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; UNCERTAINTY; VENTILATOR ASSOCIATED PNEUMONIA;

COHORT STUDIES; DATA INTERPRETATION, STATISTICAL; HUMANS; PNEUMONIA, VENTILATOR-ASSOCIATED;

EID: 75749093382     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/649929     Document Type: Article

References (40)

1. Altman DG. Statistics and ethics in medical research. III. How large a sample? Br Med J 1980;281:1336-1338.
2. 2. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 2001; 134:657-662. (Pubitemid 32322244)
3. Lenth RV. Statistical power calculations. J Anim Sci 2007; 85:E24-E29.
4. Breslow NE, Day NE. Statistical methods in cancer research. Vol 2. The design and analysis of cohort studies. Science Publication 82. Lyon, France: International Agency for Research on Cancer, 1987:1-406.
5. Schlesselman JJ. Sample size requirements in cohort and case-control studies of disease. Am J Epidemiol 1974; 99:381-384.
6. 6. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342:1887-1892. (Pubitemid 30419054)
7. 7. Cook DJ, Walter SD, Cook RJ, et al. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med 1998; 129:433-440. (Pubitemid 28428078)
8. Safdar N, Dezfulian C, Collard HR, Saint S. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med 2005; 33:2184-2193.
9. Siempos II, Athanassa Z, Falagas ME. Frequency and predictors of ventilator-associated pneumonia recurrence: a meta-analysis. Shock 2008; 30:487-495.
10. 10. Rello J, Ollendorf DA, Oster G, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002; 122:2115-2121. (Pubitemid 36051151)
11. 11. Alp E, Guven M, Yildiz O, Aygen B, Voss A, Doganay M. Incidence, risk factors and mortality of nosocomial pneumonia in intensive care units: a prospective study. Ann Clin Microbiol Antimicrob 2004; 3:17. (Pubitemid 41630810)
12. Gursel G, Demirtas S. Value of APACHE II, SOFA and CPIS scores in predicting prognosis in patients with ventilator-associated pneumonia. Respiration 2006; 73:503-508.
13. 13. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416. (Pubitemid 40227463)
14. 14. Bercault N, Boulain T. Mortality rate attributable to ventilator-associated nosocomial pneumonia in an adult intensive care unit: a prospective case-control study. Crit Care Med 2001; 29:2303-2309. (Pubitemid 34038163)
15. 15. Papazian L, Bregeon F, Thirion X, et al. Effect of ventilator-associated pneumonia on mortality and morbidity. Am J Respir Crit Care Med 1996; 154:91-97. (Pubitemid 26255772)
16. Rello J, Quintana E, Ausina V, et al. Incidence, etiology, and outcome of nosocomial pneumonia in mechanically ventilated patients. Chest 1991; 100:439-444.
17. Aarts MA, Hancock JN, Heyland D, McLeod RS, Marshall JC. Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials. Crit Care Med 2008; 36:108-117.
18. 18. Masterton RG, Galloway A, French G, et al. Guidelines for the management of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2008; 62: 5-34. (Pubitemid 351865870)
19. Review Manager (RevMan) [computer program]. Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
20. Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version 2.2.1. Updated 6 April 2008. Available at: http://www.OpenEpi.com. Accessed 18 September 2008.
21. Sedlmeier P, Gigerenzer G. Do studies of statistical power have an effect on the power of studies? Psychol Bull 1989; 105:309-316.
22. Johnson D. The insignificance of statistical significance testing. JWM 1999; 63:763-772.
23. 23. Hoenig J, Heisey D. The abuse of power: the pervasive fallacy of power calculations for data analysis. Am Stat 2001; 55:19-24. (Pubitemid 33227057)
24. Grunkemeier GL, Jin R. Power and sample size: how many patients do I need? Ann Thorac Surg 2007; 83:1934-1939.
25. Goodman SN, Berlin JA. The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. Ann Intern Med 1994; 121:200-206.
26. 26. Zumbo B, Hubley A. A note on misconceptions concerning prospective and retrospective power. J R Stat Soe Ser D Stat 1998; 47:385-388. (Pubitemid 128459062)
27. Onwuegbuzie A, Leech N. Post hoc power: a concept whose time has come. Understand Stat 2004; 3:201-230.
28. 28. Chung KC, Kalliainen LK, Spilson SV, Walters MR, Kim HM. The prevalence of negative studies with inadequate statistical power: an analysis of the plastic surgery literature. Plast Reconstr Surg 2002; 109: 1-6. (Pubitemid 34056648)
29. Lochner HV, Bhandari M, Tornetta P 3rd. Type II error rates (β errors) of randomized trials in orthopaedic trauma. J Bone Joint Surg Am 2001; 83-A:1650-A1655.
30. Chung KC, Kalliainen LK, Hayward RA. Type II (β) errors in the hand literature: the importance of power. J Hand Surg Am 1998; 23:20-25.
31. 31. McKeown-Eyssen GE, Thomas DC. Sample size determination in casecontrol studies: the influence of the distribution of exposure. J Chronic Dis 1985; 38:559-568. (Pubitemid 15073854)
32. Hiebert R, Nordin M. Methodological aspects of outcomes research. Eur Spine J 2006; 15(Suppl 1):S4-S16.
33. Edwards SJ, Lilford RJ, Braunholtz D, Jackson J. Why "underpowered" trials are not necessarily unethical. Lancet 1997; 350:804-807.
34. 34. Bacchetti P. Peer review of statistics in medical research: the other problem. BMJ 2002; 324:1271-1273. (Pubitemid 34553571)
35. Athanassa Z, Siempos II, Falagas ME. Impact of methicillin resistance on mortality in Staphylococcus aureus VAP: a systematic review. Eur Respir J 2008; 31:625-632.
36. 36. Vardakas KZ, Siempos II, Falagas ME. Diabetes mellitus as a risk factor for nosocomial pneumonia and associated mortality. Diabet Med 2007; 24:1168-1171. (Pubitemid 47437883)
37. Pocock SJ, Hughes MD, Lee RJ. Statistical problems in the reporting of clinical trials. A survey of three medical journals. N Engl J Med 1987; 317:426-432.
38. 38. Xiong C, Yu K, Gao F, Yan Y, Zhang Z. Power and sample size for clinical trials when efficacy is required in multiple endpoints: application to an Alzheimer's treatment trial. Clin Trials 2005; 2:387-393. (Pubitemid 41586023)
39. Heyland DK, Dodek P, Muscedere J, Day A, Cook D. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med 2008; 36: 737-744.
40. 40. Brun-Buisson C, Sollet JP, Schweich H, Briere S, Petit C. Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: a multicenter, randomized controlled trial. VAP Study Group. Clin Infect Dis 1998; 26:346-354. (Pubitemid 28083945)